| Literature DB >> 32205142 |
Prasanna Boddupalli1, L M Suresh2, Francis Mwatuni2, Yoseph Beyene2, Dan Makumbi2, Manje Gowda2, Mike Olsen2, David Hodson3, Mosisa Worku2, Monica Mezzalama3, Terence Molnar3, Kanwarpal S Dhugga3, Anne Wangai4, Lilian Gichuru5, Samuel Angwenyi6, Yoseph Alemayehu7, Jens Grønbech Hansen8, Poul Lassen8.
Abstract
Maize lethal necrosis (MLN), a complex viral disease, emerged as a serious threat to maize production and the livelihoods of smallholders in eastern Africa since 2011, primarily due to the introduction of maize chlorotic mottle virus (MCMV). The International Maize and Wheat Improvement Center (CIMMYT), in close partnership with national and international partners, implemented a multi-disciplinary and multi-institutional strategy to curb the spread of MLN in sub-Saharan Africa, and mitigate the impact of the disease. The strategy revolved around a) intensive germplasm screening and fast-tracked development and deployment of MLN-tolerant/resistant maize hybrids in Africa-adapted genetic backgrounds; b) optimizing the diagnostic protocols for MLN-causing viruses, especially MCMV, and capacity building of relevant public and private sector institutions on MLN diagnostics and management; c) MLN monitoring and surveillance across sub-Saharan Africa in collaboration with national plant protection organizations (NPPOs); d) partnership with the private seed sector for production and exchange of MLN pathogen-free commercial maize seed; and e) awareness creation among relevant stakeholders about MLN management, including engagement with policy makers. The review concludes by highlighting the need to keep continuous vigil against MLN-causing viruses, and preventing any further spread of the disease to the major maize-growing countries that have not yet reported MLN in sub-Saharan Africa.Entities:
Keywords: Africa; Breeding; Diagnostics; Maize chlorotic mottle virus; Maize lethal necrosis; Surveillance
Year: 2020 PMID: 32205142 PMCID: PMC7221342 DOI: 10.1016/j.virusres.2020.197943
Source DB: PubMed Journal: Virus Res ISSN: 0168-1702 Impact factor: 3.303
Fig. 1(A) MLN-resistant inbred lines, CKDHL1705340 (left) and CKDHL1705309 (right), flanking an MLN-susceptible line, CML442; (B) MLN-resistant line, KS23-6 (left) versus an MLN-susceptible line, CML547 (right), 30 days after first artificial inoculation at the MLN Screening Facility, Naivasha (Kenya).
Fig. 2Frequency distribution of maize lines (n = 5307) derived during 2014–2018 for MLN severity scores, based on evaluation under MLN artificial inoculation at Naivasha in Kenya.
List of CIMMYT-derived MLN-tolerant hybrids released till 2019 in East Africa.
| S.No. | Hybrids | Year of Release | Country | Partner organization that released the hybrid | MLN severity score (on 1-9 scale) | First- or second-generation ML |
|---|---|---|---|---|---|---|
| 1 | H6505 | 2013 | Kenya | KSC | 6 | First-generation |
| 2 | Bazooka | 2014 | Uganda | NASECO | 5 | First-generation |
| 3 | H6506 | 2014 | Kenya | KSC | 6 | First-generation |
| 4 | Meru HB607 | 2014 | Tanzania | Meru Agro Seed Company | 6 | First-generation |
| 5 | WE5135 | 2016 | Kenya; Tanzania | KALRO (Kenya); TOSCI (Tanzania) | 4 | Second-generation |
| 6 | WE5140 | 2016 | Kenya | KALRO | 4 | Second-generation |
| 7 | WE6109 | 2016 | Kenya | KALRO | 4 | Second-generation |
| 8 | WE6110 | 2016 | Kenya | KALRO | 4 | Second-generation |
| 9 | KATEH16-01 | 2017 | Kenya | KALRO | 4 | Second-generation |
| 10 | KATEH16-02 | 2017 | Kenya | KALRO | 3 | Second-generation |
| 11 | KATEH16-03 | 2017 | Kenya | KALRO | 4 | Second-generation |
| 12 | WHMLN | 2017 | Kenya | Western Seed Company | 4 | Second-generation |
| 13 | WE7117 | 2018 | Kenya | KALRO | 4 | Second-generation |
| 14 | WE7118 | 2018 | Kenya | KALRO | 3 | Second-generation |
| 15 | WE7119 | 2018 | Kenya; Tanzania | KALRO (Kenya); TOSCI (Tanzania) | 4 | Second-generation |
| 16 | WE5141 | 2019 | Tanzania | COSTEC | 4 | Second-generation |
| 17 | WE7133 | 2019 | Tanzania | COSTEC | 4 | Second-generation |
| 18 | CKMLN150074 | 2019 | Kenya | Seed Co. Ltd | 4 | Second-generation |
KSC: Kenya Seed Company; KALRO: Kenya Agriculture and Livestock Research Organization; TOSCI: Tanzania Official Seed Certification Institute.
Average score based on several trials undertaken at the MLN Screening Facility, Naivasha, during 2013-2019. Note that mean severity score of the MLN-susceptible commercial checks in eastern Africa is 7.5, as recorded in the trials at Naivasha during 2013-2019.
Performance of the first-generation and second-generation MLN-tolerant/resistant hybrids vis-à-vis commercial MLN-susceptible hybrids under MLN artificial inoculation and without MLN inoculation (control) at Naivasha, Kenya during 2016 and 2017.
| Category | No. of hybrids evaluated | Mean grain yield (t/ha) without MLN infection | Mean grain yield (t/ha) und MLN artificial inoculation | Mean MLN severity score (on a 1-9 scale) | Mean grain yield loss due to MLN (%) |
|---|---|---|---|---|---|
| Commercial MLN-susceptible hybrids | 11 | 3.0 | 0.7 | 6.8 | 77.7 |
| First-generation MLN tolerant precommercial and commercial hybrids | 18 | 4.4 | 3.4 | 5.0 | 22.9 |
| Second-generation MLN-resistant precommercial and commercial hybrids | 19 | 4.7 | 4.6 | 3.9 | 3.1 |
Number of landraces selected from different Latin American countries for their responses to MCMV infection.
| Country/Region | Selected | Races |
|---|---|---|
| Mexico | 435 | 36 |
| Guatemala | 150 | 21 |
| Venezuela | 117 | 13 |
| Peru | 108 | 20 |
| Caribbean Islands | 115 | 11 |
| Ecuador | 36 | 6 |
| Colombia | 29 | 8 |
| Guyanas | 6 | 3 |
| Argentina | 4 | 1 |
Because some races are regional (e.g., Tuxpeño) the total number of unique races was 92 (not 119).
Eleven maize landrace accessions selected for continued breeding based on greenhouse evaluations at CIMMYT-Mexico for MCMV resistance.
| Entry | Country | Race | Mean MCMV score (BLUE value) | Elite line used in breeding cross | Number of F3 lines derived |
|---|---|---|---|---|---|
| VERA179 | Mexico | Tuxpeño | 1.22 | CML537 | 33 |
| SCRO1 | Virgin Islands | Saint Croix | 1.25 | CML537 | 99 |
| RDOM169 | Dominican Republic | Tuson, Tuzon | 1.26 | CML537 | 77 |
| ECUA327 | Ecuador | Cuban Yellow Dent | 1.26 | CML537 | 54 |
| PERU558 | Peru | Arizona | 1.26 | CML537 | 7 |
| VERA203 | Mexico | Tuxpeño | 1.27 | CML537 | 18 |
| BRVI2 | British Virgin Isl. | Saint Croix | 1.28 | CML549 | 147 |
| PUER2 | Puerto Rico | Chandelle | 1.28 | CML550 | 130 |
| CUBA9 | Cuba | Cuban Flint | 1.29 | CML550 | 106 |
| HAIT44 | Haiti | Haiti White | 1.31 | CML494 | 48 |
| OAXA106 | Mexico | Conico | 1.36 | CML549 | 44 |
| CML494 | CIMMYT line (Resistant check) | – | 1.15 | – | – |
| CML550 | CIMMYT line (Resistant check) | – | 1.47 | – | – |
| CML334 | CIMMYT line (Susceptible check) | – | 1.64 | – | – |
| CML228 | CIMMYT line (Susceptible check) | – | 2.11 | – | – |
Mean MCMV score based on data from three trials; responses recorded on a 1 to 3 scale (1 = no visual MCMV symptoms; 2 = a few visual MCMV symptoms; 3 = severe MCMV symptoms).
Not enough F3 lines derived for further testing.
Fig. 3Responses of MLN-resistant versions vis-à-vis the recurrent parents (elite but MLN-susceptible lines) 30 days after first artificial inoculation at the MLN screening facility in Naivasha, Kenya. The MLN-resistant versions have qMLN_06.157 from KS23-6 (donor parent), transferred through marker-assisted backcrossing.
MCMV immunostrip data summary from 2014 to 2019 based on surveys undertaken in eight countries in eastern and southern Africa. All the data from 2016 onwards were collected using standardized diagnostics protocols. Historical data from 2014 and 2015 are included only for comparison.
| Country | MCMV data | Year | |||||
|---|---|---|---|---|---|---|---|
| 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | ||
| No data | No data | No data | |||||
| MCMV + ve | 146 | 19 | 71 | No data | No data | No data | |
| MCMV -ve | 274 | 282 | 192 | No data | No data | No data | |
| No data | No data | No data | |||||
| No data | |||||||
| MCMV + ve | 56 | 36 | 7 | No data | 54 | 24 | |
| MCMV -ve | 294 | 162 | 193 | No data | 83 | 81 | |
| No data | |||||||
| No data | No data | No data | |||||
| MCMV + ve | 22 | No data | No data | 13 | 97 | No data | |
| MCMV -ve | 44 | No data | No data | 54 | 44 | No data | |
| No data | No data | No data | |||||
| No data | No data | No data | |||||
| MCMV + ve | 38 | 19 | No data | No data | 167 | No data | |
| MCMV -ve | 439 | 157 | No data | No data | 232 | No data | |
| No data | No data | No data | |||||
| No data | |||||||
| MCMV + ve | 24 | 147 | 18 | No data | 14 | 23 | |
| MCMV -ve | 117 | 10 | 51 | No data | 231 | 335 | |
| No data | |||||||
| No data | No data | ||||||
| MCMV + ve | 0 | 0 | 0 | 0 | No data | No data | |
| MCMV -ve | 373 | 173 | 312 | 207 | No data | No data | |
| No data | No data | ||||||
| No data | No data | ||||||
| MCMV + ve | 0 | 0 | 0 | 0 | No data | No data | |
| MCMV -ve | 240 | 179 | 335 | 128 | No data | No data | |
| No data | No data | ||||||
| No data | No data | ||||||
| MCMV + ve | 0 | 0 | 0 | 0 | No data | No data | |
| MCMV -ve | 265 | 280 | 284 | 223 | No data | No data | |
| No data | No data | ||||||
Fig. 4Results of MLN surveys (based on MCMV immunostrip data, coupled with evaluation for MLN symptoms, if any) undertaken by NPPOs in eastern and southern Africa, in partnership with CIMMYT, in (A) 2017 versus (B) 2018 versus (C) 2019.